Concepedia

Author

Julieta Grasselli

Institut Català d'Oncologia

Also Known As

J. Grasselli, Julieta Grasselli

51

Publications

1.4K

Citations

10

H-Index

28

Concepts

All Affiliations

Institut Català d'OncologiaIstituto Nazionale Tumori IRCCS "Fondazione G. Pascale"KU LeuvenHospital Italiano de Buenos AiresUniversitat Autònoma de Barcelona
JG

About

Julieta Grasselli is an author at Institut Català d'Oncologia specializing in oncology, radiation oncology, and medicine.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

966

2

Engineering

1

1

17

3

Health Sciences

1

1

26

4

Biomedical Engineering

1

1

17

5

Biostatistics

1

1

17

Julieta Grasselli

×

8

Publications

1.4K

Citations

8

H-Index

YearCitations

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Robin Kate Kelley, Makoto Ueno, Changhoon Yoo,

The Lancet

2023

891

Concordance of blood- and tumor-based detection of RAS mutations to guide anti-EGFR therapy in metastatic colorectal cancer

Julieta Grasselli, Élena Elez, Ginevra Caratù,

Annals of Oncology

2017

189

Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in <i>BRAF</i> -Mutant Colorectal Cancer

Daniele Oddo, Erin M. Sennott, Ludovic Barault,

Cancer Research

2016

119

Impact of circulating tumor DNA mutant allele fraction on prognosis in <i>RAS</i>‐mutant metastatic colorectal cancer

Élena Elez, Chiara Chianese, Enrique Sanz‐García,

Molecular Oncology

2019

52

TGF-beta specifically enhances the metastatic attributes of murine lung adenocarcinoma: implications for human non-small cell lung cancer

Paula Vázquez, María J. Carlini, María Cecilia Daroqui,

Clinical & Experimental Metastasis

2013

32

Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

Michael Schenker, Mauricio Burotto, Martin Eduardo Richardet,

Journal for ImmunoTherapy of Cancer

2024

32

Abstract CT022: CheckMate 848: A randomized, open-label, phase 2 study of nivolumab in combination with ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden

Michael Schenker, Mauricio Burotto, Martin Eduardo Richardet,

Cancer Research

2022

26

Nanofluidic Digital PCR and Extended Genotyping of <i>RAS</i> and <i>BRAF</i> for Improved Selection of Metastatic Colorectal Cancer Patients for Anti-EGFR Therapies

Daniel Azuara, Cristina Santos, Adriana López‐Doriga,

Molecular Cancer Therapeutics

2016

17

Page 1